Halozyme Therapeutics (HALO) EBT (2010 - 2026)

Halozyme Therapeutics (HALO) has 17 years of EBT data on file, last reported at $180.3 million in Q1 2026.

• On a quarterly basis, EBT rose 25.38% year-over-year to $180.3 million in Q1 2026; TTM through Mar 2026 was $503.4 million, a 16.79% decrease from a year earlier, with the FY2025 full-year figure at $466.9 million, down 16.2% from the prior year.
• EBT for Q1 2026 stood at $180.3 million, up from -$100.8 million in the prior quarter.
• Over the last five years, EBT for HALO reached as high as $219.0 million in Q3 2025 and fell as low as -$100.8 million in Q4 2025.
• Historically, EBT has averaged $106.0 million across 5 years, with a median of $101.2 million in 2023.
• Across the five-year window, EBT jumped 210.41% in 2023 and slumped 156.59% in 2025, its largest moves.
• Year by year, EBT stood at $70.8 million in 2022, then soared by 42.92% to $101.2 million in 2023, then jumped by 76.14% to $178.2 million in 2024, then slumped by 156.59% to -$100.8 million in 2025, then surged by 278.81% to $180.3 million in 2026.
• Per Business Quant data, the three most recent EBT figures were $180.3 million in Q1 2026, -$100.8 million in Q4 2025, and $219.0 million in Q3 2025.